scholarly journals Concomitant Diagnosis of Primary Bone Marrow B-Cell Non-Hodgkin Lymphoma and Essential Thrombocythemia: A Case Report

2022 ◽  
Vol 42 (2) ◽  
pp. 282-285
Author(s):  
Hongkyung Kim ◽  
Hye Min Kim ◽  
Jin Ju Kim ◽  
Saeam Shin ◽  
Doh Yu Hwang ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Case Report ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Essential Thrombocythemia ◽  
Non Hodgkin Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow

scholarly journals Aggressive CD5-Positive Primary Bone Marrow Diffuse Large B-Cell Lymphoma with Leukemic Presentation

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Mark G. Evans ◽  
Sherif A. Rezk ◽  
Lauren C. Pinter-Brown ◽  
Xiaohui Zhao
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Intrathecal Methotrexate ◽  
Non Hodgkin Lymphoma ◽  
Large B Cell Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

Primary bone marrow diffuse large B-cell lymphoma is an exceedingly rare form of non-Hodgkin lymphoma. It may demonstrate a leukemic presentation, and a proportion of cases have CD5 expression. The prognostic implications of this CD5-positivity remain unknown. Here, we present a 78-year-old man who presented with circulating peripheral blood lymphoma cells and a hypercellular marrow involved by diffuse large B-cell lymphoma, germinal center B-cell subtype. The patient responded favorably to six cycles of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) and intrathecal methotrexate. He unfortunately relapsed in several enlarged inguinal lymph nodes and succumbed to the lymphoma approximately one year after diagnosis, demonstrating the particularly aggressive clinical course of his disease.

scholarly journals Fever and arthralgia as the initial symptoms of primary bone marrow diffuse large B-cell lymphoma: A case report

2016 ◽  
Vol 11 (5) ◽  
pp. 3428-3432 ◽  
Author(s):  
SAISAI REN ◽  
YANLING TAO ◽  
LU JIA ◽  
PANPAN CHENG ◽  
JILEI ZHANG ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Case Report ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Initial Symptoms ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

PO44 Primary bone marrow diffuse large B cell lymphoma: a case report

2012 ◽  
Vol 82 ◽  
pp. S25
Author(s):  
A. Escriva Vicedo ◽  
A. Tolosa ◽  
J. Ros Soto ◽  
A. Garcia Feria ◽  
M.J. Cejalvo Andújar ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Case Report ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

scholarly journals Case Report Diffuse large B-cell lymphoma in the primary bone marrow

2015 ◽  
Vol 14 (2) ◽  
pp. 6247-6250 ◽  
Author(s):  
Y. Hu ◽  
S.L. Chen ◽  
Z.X. Huang ◽  
W. Gao ◽  
N. An
Keyword(s):  
Bone Marrow ◽  
Case Report ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

scholarly journals FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

2021 ◽  
Author(s):  
Dominic Kaddu-Mulindwa ◽  
Bettina Altmann ◽  
Gerhard Held ◽  
Stephanie Angel ◽  
Stephan Stilgenbauer ◽  
...  
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Predictive Value ◽  
Fdg Pet ◽  
Bone Marrow Involvement ◽  
Non Hodgkin Lymphoma ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Initial Staging

Abstract Purpose Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to determine whether initial staging by FDG PET/CT provides treatment-relevant information of bone marrow (BM) involvement (BMI) and thus could spare BM biopsy (BMB). Methods Patients from PETAL (NCT00554164) and OPTIMAL>60 (NCT01478542) with aggressive B-cell NHL initially staged by FDG PET/CT and BMB were included in this pooled analysis. The reference standard to confirm BMI included a positive BMB and/or FDG PET/CT confirmed by targeted biopsy, complementary imaging (CT or magnetic resonance imaging), or concurrent disappearance of focal FDG-avid BM lesions with other lymphoma manifestations during immunochemotherapy. Results Among 930 patients, BMI was detected by BMB in 85 (prevalence 9%) and by FDG PET/CT in 185 (20%) cases, for a total of 221 cases (24%). All 185 PET-positive cases were true positive, and 709 of 745 PET-negative cases were true negative. For BMB and FDG PET/CT, sensitivity was 38% (95% confidence interval [CI]: 32–45%) and 84% (CI: 78–88%), specificity 100% (CI: 99–100%) and 100% (CI: 99–100%), positive predictive value 100% (CI: 96–100%) and 100% (CI: 98–100%), and negative predictive value 84% (CI: 81–86%) and 95% (CI: 93–97%), respectively. In all of the 36 PET-negative cases with confirmed BMI patients had other adverse factors according to IPI that precluded a change of standard treatment. Thus, the BMB would not have influenced the patient management. Conclusion In patients with aggressive B-cell NHL, routine BMB provides no critical staging information compared to FDG PET/CT and could therefore be omitted. Trial registration NCT00554164 and NCT01478542

HL-243: Unusual Primary Bone Marrow Hodgkin Lymphoma Presentation–Epidemiological Data from the University Clinical Center of Kosovo Between 2009–2020

2021 ◽  
Vol 21 ◽  
pp. S371-S372
Author(s):  
Miranda Hoti ◽  
Shemsedin Sadiku ◽  
Aferdita Ukimeraj ◽  
Viola Cavolli ◽  
Gresa Elezi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Hodgkin Lymphoma ◽  
Epidemiological Data ◽  
Clinical Center ◽  
Primary Bone ◽  
The University ◽  
Primary Bone Marrow
Sign in / Sign up

Export Citation Format

Share Document